JP2012504122A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504122A5 JP2012504122A5 JP2011529021A JP2011529021A JP2012504122A5 JP 2012504122 A5 JP2012504122 A5 JP 2012504122A5 JP 2011529021 A JP2011529021 A JP 2011529021A JP 2011529021 A JP2011529021 A JP 2011529021A JP 2012504122 A5 JP2012504122 A5 JP 2012504122A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- independently
- aliphatic
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001931 aliphatic group Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 16
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 125000004432 carbon atom Chemical group C* 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000003373 pyrazinyl group Chemical group 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 4
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
- 150000008064 anhydrides Chemical class 0.000 claims 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 3
- 125000005434 dihydrobenzoxazinyl group Chemical group O1N(CCC2=C1C=CC=C2)* 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- -1 tetrahydroquinoxalinyl Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 239000008139 complexing agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19461408P | 2008-09-29 | 2008-09-29 | |
| US61/194,614 | 2008-09-29 | ||
| PCT/US2009/005324 WO2010036357A1 (en) | 2008-09-29 | 2009-09-25 | Derivatives of 1-amino-2-cyclobutylethylboronic acid |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015085803A Division JP2015143264A (ja) | 2008-09-29 | 2015-04-20 | １−アミノ−２−シクロブチルエチルボロン酸の誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012504122A JP2012504122A (ja) | 2012-02-16 |
| JP2012504122A5 true JP2012504122A5 (enExample) | 2012-11-15 |
| JP5736314B2 JP5736314B2 (ja) | 2015-06-17 |
Family
ID=41426361
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011529021A Active JP5736314B2 (ja) | 2008-09-29 | 2009-09-25 | １−アミノ−２−シクロブチルエチルボロン酸の誘導体 |
| JP2015085803A Pending JP2015143264A (ja) | 2008-09-29 | 2015-04-20 | １−アミノ−２−シクロブチルエチルボロン酸の誘導体 |
| JP2016199804A Pending JP2017025091A (ja) | 2008-09-29 | 2016-10-11 | １−アミノ−２−シクロブチルエチルボロン酸の誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015085803A Pending JP2015143264A (ja) | 2008-09-29 | 2015-04-20 | １−アミノ−２−シクロブチルエチルボロン酸の誘導体 |
| JP2016199804A Pending JP2017025091A (ja) | 2008-09-29 | 2016-10-11 | １−アミノ−２−シクロブチルエチルボロン酸の誘導体 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US8664200B2 (enExample) |
| EP (1) | EP2346882B1 (enExample) |
| JP (3) | JP5736314B2 (enExample) |
| KR (1) | KR101739470B1 (enExample) |
| CN (2) | CN103554143B (enExample) |
| AR (1) | AR075090A1 (enExample) |
| AU (1) | AU2009297113B2 (enExample) |
| BR (1) | BRPI0919447B8 (enExample) |
| CA (1) | CA2739375C (enExample) |
| CL (1) | CL2011000653A1 (enExample) |
| CO (1) | CO6362015A2 (enExample) |
| CR (2) | CR20160475A (enExample) |
| DO (1) | DOP2011000086A (enExample) |
| EA (1) | EA030539B1 (enExample) |
| EC (1) | ECSP11011011A (enExample) |
| IL (1) | IL211983A0 (enExample) |
| MA (1) | MA32729B1 (enExample) |
| MX (1) | MX2011003317A (enExample) |
| MY (1) | MY166653A (enExample) |
| NZ (2) | NZ606001A (enExample) |
| SG (1) | SG194388A1 (enExample) |
| TW (2) | TWI598352B (enExample) |
| UA (1) | UA105503C2 (enExample) |
| WO (1) | WO2010036357A1 (enExample) |
| ZA (1) | ZA201203615B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7687456B2 (en) | 2005-11-09 | 2010-03-30 | Proteolix, Inc. | Compounds for enzyme inhibition |
| EP2484688B1 (en) | 2006-06-19 | 2016-06-08 | Onyx Therapeutics, Inc. | Peptide epoxyketones for proteasome inhibition |
| MX2010003732A (es) | 2007-10-04 | 2010-08-09 | Onyx Therapeutics Inc | Inhibidores de peptido cetona epoxi de proteasa cristalina y la sintesis de ceto-epoxidos de aminoacido. |
| BR122014008753A2 (pt) | 2008-06-17 | 2015-12-29 | Millennium Pharm Inc | compostos de éster boronato e composições farmacêuticas dos mesmos |
| PE20120059A1 (es) | 2008-10-21 | 2012-02-27 | Onyx Therapeutics Inc | Combinaciones farmaceuticas con epoxicetonas peptidicas |
| TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
| US8853147B2 (en) | 2009-11-13 | 2014-10-07 | Onyx Therapeutics, Inc. | Use of peptide epoxyketones for metastasis suppression |
| US9359398B2 (en) * | 2010-03-01 | 2016-06-07 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
| CN106008570A (zh) | 2010-03-31 | 2016-10-12 | 米伦纽姆医药公司 | 1-氨基-2-环丙基乙硼酸衍生物 |
| US20150184246A1 (en) | 2011-11-11 | 2015-07-02 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
| JP6397765B2 (ja) | 2011-11-11 | 2018-09-26 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | プロテアソーム阻害剤に応答するバイオマーカー |
| SG10201605152SA (en) * | 2011-12-22 | 2016-08-30 | Ares Trading Sa | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
| CA2862492A1 (en) | 2012-01-24 | 2013-08-01 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
| US9309283B2 (en) | 2012-07-09 | 2016-04-12 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
| JP6018319B2 (ja) * | 2012-12-03 | 2016-11-02 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 置換トリアゾールボロン酸化合物 |
| KR20160058886A (ko) | 2013-10-03 | 2016-05-25 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 전신 홍반성 낭창 및/또는 낭창성 신염의 예방 또는 치료 방법 |
| ES2748434T3 (es) | 2014-01-10 | 2020-03-16 | Univ Cornell | Dipéptidos como inhibidores de inmunoproteasomas humanos |
| CN106659761A (zh) | 2014-05-20 | 2017-05-10 | 千年药物公司 | 初级癌症疗法后使用的含硼蛋白酶体抑制剂 |
| EP3808349B1 (en) | 2014-08-07 | 2022-10-05 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
| EP3193904B1 (en) | 2014-08-18 | 2025-10-01 | Cornell University | Dipeptidomimetics as inhibitors of human immunoproteasomes |
| JP6662865B2 (ja) * | 2014-10-01 | 2020-03-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ボロン酸誘導体 |
| AU2015327411B2 (en) * | 2014-10-01 | 2020-01-02 | Merck Patent Gmbh | Boronic acid derivatives |
| SG11201702623TA (en) * | 2014-10-01 | 2017-04-27 | Merck Patent Gmbh | Boronic acid derivatives |
| CA2963198A1 (en) * | 2014-10-01 | 2016-04-07 | Merck Patent Gmbh | Boronic acid derivatives |
| JP6970085B2 (ja) | 2015-10-15 | 2021-11-24 | コーネル・ユニバーシティーCornell University | プロテアソーム阻害剤およびその用途 |
| MX392422B (es) | 2016-06-21 | 2025-03-24 | Orion Ophthalmology LLC | Derivados de prolinamida heterociclica |
| JP7164521B2 (ja) | 2016-06-21 | 2022-11-01 | オリオン・オフサルモロジー・エルエルシー | 炭素環式プロリンアミド誘導体 |
| ES3036483T3 (en) | 2017-02-28 | 2025-09-19 | Mayo Found Medical Education & Res | Combinations for use in the treatment of cancer |
| US11203613B2 (en) | 2017-10-11 | 2021-12-21 | Cornell University | Peptidomimetic proteasome inhibitors |
| US11243207B2 (en) | 2018-03-29 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Assessing and treating cancer |
| LT3952995T (lt) | 2019-04-12 | 2023-11-10 | Riboscience Llc | Bicikliniai heteroarilo dariniai kaip ektonukleotidų pirofosfatazės fosfodiesterazės 1 inhibitoriai |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ203706A (en) | 1982-04-22 | 1986-03-14 | Squibb & Sons Inc | Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment |
| US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
| US5242904A (en) | 1987-06-05 | 1993-09-07 | The Dupont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| US5250720A (en) | 1987-06-05 | 1993-10-05 | The Dupont Merck Pharmaceutical Company | Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases |
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| EP0315574A3 (de) | 1987-11-05 | 1990-08-22 | Hoechst Aktiengesellschaft | Renin-Inhibitoren |
| US5159060A (en) | 1988-05-27 | 1992-10-27 | Mayo Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
| US5106948A (en) | 1988-05-27 | 1992-04-21 | Mao Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
| DE3827340A1 (de) | 1988-08-12 | 1990-02-15 | Hoechst Ag | Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen |
| ATE149563T1 (de) | 1992-08-14 | 1997-03-15 | Procter & Gamble | Alpha-aminoborsäurehaltige flüssige waschmittel |
| US5492900A (en) | 1993-09-10 | 1996-02-20 | Neutron Technology Corporation | Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA) |
| US5935944A (en) | 1993-09-10 | 1999-08-10 | Neutron Technology Corporation | Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA) |
| US6060462A (en) | 1993-10-20 | 2000-05-09 | Dupont Pharmaceuticals Company | Electrophilic peptide analogs as inhibitors of trypsin-like enzymes |
| US5574017A (en) | 1994-07-05 | 1996-11-12 | Gutheil; William G. | Antibacterial agents |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US5614649A (en) | 1994-11-14 | 1997-03-25 | Cephalon, Inc. | Multicatalytic protease inhibitors |
| AU741802B2 (en) | 1997-02-15 | 2001-12-13 | Millennium Pharmaceuticals, Inc. | Treatment of infarcts through inhibition of NF-kappaB |
| AU9580098A (en) | 1997-09-25 | 1999-04-12 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-(k)b via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases |
| CN1282242A (zh) | 1997-12-16 | 2001-01-31 | 赛福伦公司 | 多相催化蛋白酶抑制剂用作抗肿瘤剂 |
| US6169076B1 (en) | 1999-03-31 | 2001-01-02 | Glcosyn Pharmaceuticals, Inc. | P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols |
| EP1196436A2 (en) | 1999-07-07 | 2002-04-17 | Bristol-Myers Squibb Pharma Company | Peptide boronic acid inhibitors of hepatitis c virus protease |
| US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
| EP2251344B2 (en) | 2001-01-25 | 2024-04-24 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Formulation of boronic acid compounds |
| WO2002096933A1 (en) | 2001-05-30 | 2002-12-05 | Novartis Ag | 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives |
| JPWO2003033507A1 (ja) | 2001-10-12 | 2005-02-03 | 杏林製薬株式会社 | ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬 |
| AU2003219652A1 (en) | 2002-01-08 | 2003-07-30 | Eisai Co. Ltd. | Eponemycin and epoxomicin analogs and uses thereof |
| WO2003105860A1 (en) | 2002-06-14 | 2003-12-24 | Novo Nordisk A/S | Pharmaceutical use of boronic acids and esters thereof |
| US20060084592A1 (en) | 2002-09-09 | 2006-04-20 | Trigen Limited | Peptide boronic acid inhibitors |
| TW200418791A (en) | 2003-01-23 | 2004-10-01 | Bristol Myers Squibb Co | Pharmaceutical compositions for inhibiting proteasome |
| CN1867572B (zh) * | 2003-08-14 | 2012-03-28 | 赛福伦公司 | 蛋白酶体抑制剂及其使用方法 |
| US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| US7223745B2 (en) | 2003-08-14 | 2007-05-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| GB0405267D0 (en) | 2004-03-09 | 2004-04-21 | Trigen Ltd | Compounds |
| PL4008721T3 (pl) | 2004-03-30 | 2024-05-13 | Millennium Pharmaceuticals, Inc. | Synteza związków estrów i kwasów boronowych |
| US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| KR20080030079A (ko) | 2005-07-05 | 2008-04-03 | 트러스티즈 오브 터프츠 칼리지 | 섬유아세포 활성 단백질 알파의 억제제 |
| JP2009524681A (ja) | 2006-01-27 | 2009-07-02 | フェノミックス コーポレーション | Ｃ型肝炎ウイルスセリンプロテアーゼインヒビターおよびそのための使用 |
| WO2009006473A2 (en) | 2007-07-05 | 2009-01-08 | Trustees Of Tufts College | Pro-soft polypeptide proteasome inhibitors, and methods of use thereof |
| GEP20125599B (en) | 2007-08-06 | 2012-08-10 | Millennium Pharm Inc | Proteasome inhibitors |
| US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
| BR122014008753A2 (pt) | 2008-06-17 | 2015-12-29 | Millennium Pharm Inc | compostos de éster boronato e composições farmacêuticas dos mesmos |
| CN106008570A (zh) | 2010-03-31 | 2016-10-12 | 米伦纽姆医药公司 | 1-氨基-2-环丙基乙硼酸衍生物 |
-
2009
- 2009-09-12 AR ARP090103760A patent/AR075090A1/es not_active Application Discontinuation
- 2009-09-25 CA CA2739375A patent/CA2739375C/en active Active
- 2009-09-25 BR BRPI0919447A patent/BRPI0919447B8/pt active IP Right Grant
- 2009-09-25 UA UAA201105450A patent/UA105503C2/uk unknown
- 2009-09-25 CN CN201310475757.1A patent/CN103554143B/zh active Active
- 2009-09-25 KR KR1020117009732A patent/KR101739470B1/ko not_active Expired - Fee Related
- 2009-09-25 CR CR20160475A patent/CR20160475A/es unknown
- 2009-09-25 CN CN200980144074XA patent/CN102203103A/zh active Pending
- 2009-09-25 NZ NZ606001A patent/NZ606001A/en not_active IP Right Cessation
- 2009-09-25 US US12/586,650 patent/US8664200B2/en active Active
- 2009-09-25 SG SG2013073267A patent/SG194388A1/en unknown
- 2009-09-25 EA EA201170508A patent/EA030539B1/ru not_active IP Right Cessation
- 2009-09-25 JP JP2011529021A patent/JP5736314B2/ja active Active
- 2009-09-25 EP EP09789372.1A patent/EP2346882B1/en active Active
- 2009-09-25 MY MYPI2011001392A patent/MY166653A/en unknown
- 2009-09-25 NZ NZ592497A patent/NZ592497A/xx not_active IP Right Cessation
- 2009-09-25 WO PCT/US2009/005324 patent/WO2010036357A1/en not_active Ceased
- 2009-09-25 MX MX2011003317A patent/MX2011003317A/es active IP Right Grant
- 2009-09-25 AU AU2009297113A patent/AU2009297113B2/en not_active Ceased
- 2009-09-29 TW TW105105530A patent/TWI598352B/zh not_active IP Right Cessation
- 2009-09-29 TW TW098133005A patent/TW201024313A/zh unknown
-
2011
- 2011-03-25 CL CL2011000653A patent/CL2011000653A1/es unknown
- 2011-03-28 IL IL211983A patent/IL211983A0/en unknown
- 2011-03-28 DO DO2011000086A patent/DOP2011000086A/es unknown
- 2011-04-26 MA MA33796A patent/MA32729B1/fr unknown
- 2011-04-26 CR CR20110216A patent/CR20110216A/es unknown
- 2011-04-27 CO CO11051428A patent/CO6362015A2/es active IP Right Grant
- 2011-04-28 EC EC2011011011A patent/ECSP11011011A/es unknown
-
2012
- 2012-05-17 ZA ZA2012/03615A patent/ZA201203615B/en unknown
-
2014
- 2014-01-13 US US14/153,752 patent/US9771381B2/en not_active Expired - Fee Related
-
2015
- 2015-04-20 JP JP2015085803A patent/JP2015143264A/ja active Pending
-
2016
- 2016-10-11 JP JP2016199804A patent/JP2017025091A/ja active Pending
-
2017
- 2017-08-18 US US15/680,514 patent/US10035811B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012504122A5 (enExample) | ||
| RU2012146819A (ru) | Ингибиторы аргиназы и их терапевтические применения | |
| TW201039865A (en) | Lyophilized preparations of proteasome inhibitors | |
| JPH07108855B2 (ja) | 循環器治療薬として有用な酸化窒素―第一級アミン安定化コンプレックス | |
| JP2013544261A5 (enExample) | ||
| JP2009519222A5 (enExample) | ||
| JP2013526501A5 (enExample) | ||
| JP2014518882A5 (enExample) | ||
| RU2012146101A (ru) | Производные 1-амино-2-циклопропилэтилбороновой кислоты | |
| JP2017531624A5 (enExample) | ||
| JP2015501833A5 (enExample) | ||
| JP2015034182A5 (enExample) | ||
| AR075090A1 (es) | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. | |
| PT1695991E (pt) | Complexo de coordenação de diaminociclohexano platina (ii) com copolímero de bloco contendo segmento poli(ácido carboxílico) e agente antitumoral compreendendo o mesmo | |
| JP2013532729A5 (enExample) | ||
| JP2014508814A (ja) | リチウム組成物 | |
| CN1505513A (zh) | 注射用西洛他唑水性制剂 | |
| JP2022081630A (ja) | ベンゾアゼピン化合物含有凍結乾燥組成物 | |
| RU2013136861A (ru) | Новое производное индола или индазола или его соль | |
| JP5086497B1 (ja) | ボロン酸化合物を含有したブロック共重合体を含む医薬組成物 | |
| JP2006503805A5 (enExample) | ||
| US20140072604A1 (en) | Block Copolymer For Intraperitoneal Administration Containing Anti-Cancer Agent, Micelle Preparation Thereof, And Cancer Therapeutic Agent Comprising The Micelle Preparation As Active Ingredient | |
| RU2015113959A (ru) | Индолины | |
| ES2552734T3 (es) | Compuestos para usar en el tratamiento del cáncer | |
| WO2006082490A1 (en) | Injectable formulations of benzimidazole compounds |